ClinicalTrials.gov
ClinicalTrials.gov Menu

The Role of the Vagus Nerve in Tumor-to-Brain Communication in Lung Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00397124
Recruitment Status : Unknown
Verified November 2006 by Rambam Health Care Campus.
Recruitment status was:  Recruiting
First Posted : November 8, 2006
Last Update Posted : November 8, 2006
Sponsor:
Information provided by:
Rambam Health Care Campus

Brief Summary:
the aim of this study is to measure brain metabolism in patients with lung cancer.FDG uptake in the brain in patients with malignant tumors will be compared to the amount of tracer activity found in patients who have benign pulmonary process. if differences between the brain uptake of FDG in the two groups will be found, further assessment will be performed in order to evaluate if such differences could be attributed and specifically localized to the brain regions innervated by the vagus

Condition or disease Intervention/treatment Phase
Lung Cancer Device: PET/CT imaging Not Applicable

Study Type : Interventional  (Clinical Trial)
Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Does the Vagus Nerve Play a Role in Tumor-to-Brain Communication? a Preliminary Study in Patients With Newly Diagnosed Lung Cancer
Study Start Date : April 2002

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources




Primary Outcome Measures :
  1. the impact of the imaging modality on patients management

Secondary Outcome Measures :
  1. the impact of the imaging modality on patients management


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with SPN referred for routine whole body FDG-PET imaging
  • patients with NSCLC and patients with no evidence of lung cancer on further follow up

Exclusion Criteria:

  • patients with a clinical history of vagotomy, abdominal surgery. brain tumor, brain trauma or CVA. or those with a systemic inflammatory disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00397124


Contacts
Contact: Alex Frenkel, Ph.D 972-4-8543009 a_frenkel@rambam.health.gov.il

Locations
Israel
Rambam Medical Center Recruiting
Haifa, Israel
Contact: Alex Frenkel, Ph.D    972-4-8543009    a_frenkel@rambam.health.gov.il   
Sponsors and Collaborators
Rambam Health Care Campus
Investigators
Principal Investigator: Ora Israel, MD Rambam Health Care Campus

ClinicalTrials.gov Identifier: NCT00397124     History of Changes
Other Study ID Numbers: vagusCTIL
First Posted: November 8, 2006    Key Record Dates
Last Update Posted: November 8, 2006
Last Verified: November 2006

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases